시장보고서
상품코드
1485065

천식 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 제품별, 투여 경로별, 지역별, 경쟁사별(2019-2029년)

Asthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Product (Inhalers, Nebulizers), By Route of Administration, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 182 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

천식 치료제 세계 시장 규모는 2023년 235억 2,000만 달러에 달했으며, 예측 기간 동안 2029년까지 연평균 3.25%의 안정적인 성장세를 보일 것으로 전망됩니다.

천식은 여전히 전 세계 수백만 명에게 영향을 미치고 전 세계 의료 시스템에 도전이 되고 있는 세계 건강 문제입니다. 천식 유병률이 꾸준히 증가함에 따라 세계 천식 치료제 시장은 환자와 의료진의 요구를 충족시키기 위해 빠르게 진화하고 있습니다. 기도의 염증과 수축을 특징으로 하는 천식은 천명, 호흡곤란, 기침, 흉부 압박감 등 다양한 증상으로 나타납니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 235억 2,000만 달러
시장 규모 : 2029년 283억 8,000만 달러
CAGR : 2024-2029년 3.25%
급성장 부문 병용 요법
최대 시장 북미

흡입 코르티코스테로이드, 류코트리엔 조절제, 장시간 작용하는 베타 작용제는 천식 치료를 위해 일반적으로 처방되는 약물 중 하나입니다. 이들 약물은 근본적인 염증과 기관지 수축을 표적으로 삼아 증상을 완화하고 악화를 예방하는 데 도움이 됩니다. 또한, 알부테롤과 같은 속효성 베타 작용제는 급성 천식 발작 시 즉각적인 증상 완화를 위해 종종 사용되며, 빠른 기관지 확장을 통해 기류를 개선하고 증상을 완화하는 데 도움을 줍니다. 세계 천식 치료제 시장은 천식 관리를 더욱 발전시키고 개선할 준비가 되어 있습니다. 새로운 생물학적 제제 및 기타 새로운 치료제의 도입을 포함한 의약품 개발의 혁신은 중증 천식 환자들에게 새로운 치료 옵션을 제공할 수 있는 잠재력을 가지고 있습니다. 특히 생물학적 제제는 천식 발병에 관여하는 특정 경로를 표적으로 삼아 환자 개개인의 필요에 맞는 맞춤 치료 접근법을 제공합니다. 이러한 치료법의 발전은 천식 관리에 혁명을 불러일으킬 수 있으며, 환자들에게 더 나은 치료 결과와 삶의 질을 향상시킬 수 있습니다.

천식의 유전적, 분자적 기반에 대한 지속적인 연구는 맞춤 치료 전략을 촉진하고 질병에 대한 이해를 높이는 데 도움이 될 것으로 기대됩니다. 연구자들은 천식 발병률 및 중증도와 관련된 유전자 마커 및 분자 경로를 확인함으로써 천식을 유발하는 근본적인 메커니즘을 다루는 표적 치료제를 개발하고자 합니다. 유전자 프로파일링과 바이오마커 분석에 기반한 맞춤 치료 계획을 통해 의료진은 환자 개개인프로파일에 맞는 치료를 할 수 있게 되어 치료 결과를 최적화하고 부작용을 최소화할 수 있을 것으로 기대됩니다. 세계 천식 치료제 시장은 전 세계 천식 환자들 증가하는 천식 부담에 대응하여 지속적으로 발전하고 있습니다. 의학 연구, 의약품 개발 및 맞춤 의료의 발전은 천식 환자들에게 새로운 희망을 가져다주고, 다양한 치료 옵션을 제공하며, 천식 관리를 개선할 수 있도록 돕고 있습니다. 혁신적인 치료법과 맞춤 치료 접근법을 활용하면 의료진은 천식 환자의 요구를 더 잘 충족시켜 증상 부담을 줄이고 악화를 예방하며 삶의 질을 향상시킬 수 있습니다.

주요 시장 성장 촉진요인

천식 유병률 증가

의료비 지출 증가

주요 시장 과제

제네릭 의약품의 경쟁사

주요 시장 동향

기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 천식 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 클래스별(항염증제, 병용요법제, 기관지 확장제)
    • 제품별(흡입기(드라이 파우더 흡입기, 정량 흡입기, 소프트 미스트 흡입기), 네뷸라이저)
    • 투여 경로별(경구, 흡입, 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 약제 클래스별
    • 제품별
    • 투여 경로별
    • 지역별

제5장 아시아태평양의 천식 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 제품별
    • 투여 경로별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 천식 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 제품별
    • 투여 경로별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 천식 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 제품별
    • 투여 경로별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 천식 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 제품별
    • 투여 경로별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 천식 치료제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 제품별
    • 투여 경로별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 천식 치료제 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Teva Pharmaceutical Industries Ltd.
  • GSK plc.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc.
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Koninklijke Philips N.V.
  • Becton, Dickinson and Company
  • Sunovion Pharmaceuticals, Inc.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Asthma Therapeutics Market was valued at USD 23.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 3.25% through 2029. Asthma remains a significant global health concern, affecting millions of individuals worldwide and posing challenges for healthcare systems across the globe. With its prevalence steadily increasing, the global asthma therapeutics market has been evolving rapidly to meet the needs of patients and healthcare providers. Characterized by airway inflammation and constriction, asthma manifests through various symptoms such as wheezing, shortness of breath, coughing, and chest tightness.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 23.52 Billion
Market Size 2029USD 28.38 Billion
CAGR 2024-20293.25%
Fastest Growing SegmentCombination Therapy
Largest MarketNorth America

Inhaled corticosteroids, leukotriene modifiers, and long-acting beta-agonists are among the commonly prescribed medications for asthma management. These medications help alleviate symptoms and prevent exacerbations by targeting underlying inflammation and bronchial constriction. Additionally, short-acting beta-agonists such as albuterol are often used for immediate symptom relief during acute asthma attacks, providing rapid bronchodilation to improve airflow and alleviate symptoms. The global asthma therapeutics market is poised for further evolution and improvement in asthma management. Innovations in drug development, including the introduction of new biologics and other novel therapies, hold promise for providing additional treatment options for patients with severe and uncontrolled asthma. Biologics, in particular, target specific pathways involved in asthma pathogenesis, offering personalized treatment approaches tailored to individual patient needs. These advancements in treatment modalities have the potential to revolutionize asthma management, offering better outcomes and improved quality of life for patients.

Ongoing research into the genetic and molecular basis of asthma is expected to drive personalized treatment strategies and enhance our understanding of the disease. By identifying genetic markers and molecular pathways associated with asthma susceptibility and severity, researchers aim to develop targeted therapies that address the underlying mechanisms driving the disease. Personalized treatment plans based on genetic profiling and biomarker analysis could enable healthcare providers to tailor therapies to individual patient profiles, optimizing treatment outcomes and minimizing adverse effects. The global asthma therapeutics market continues to evolve in response to the growing burden of asthma worldwide. Advances in medical research, drug development, and personalized medicine offer new hope for patients with asthma, providing a range of treatment options and improving overall asthma management. By leveraging innovative therapies and personalized treatment approaches, healthcare providers can better meet the needs of patients with asthma, reducing symptom burden, preventing exacerbations, and improving quality of life.

Key Market Drivers

Rising Prevalence of Asthma

Asthma is a global health concern, affecting people of all ages, from children to the elderly. The burden of asthma is not just limited to its prevalence but extends to its impact on patients' lives and healthcare costs. Several factors contribute to the increasing prevalence of asthma. Exposure to various environmental triggers such as allergens, air pollution, and tobacco smoke can increase the risk of asthma. Urbanization and industrialization have led to increased exposure to these triggers in many parts of the world. A family history of asthma or allergic conditions can predispose individuals to the development of asthma. Genetic factors play a significant role in susceptibility to the disease.

Sedentary lifestyles, changes in dietary habits, and increased stress levels have been linked to the rising prevalence of asthma. These factors can lead to obesity, which is a known risk factor for asthma. Improved diagnostic methods and increased awareness about asthma have led to more individuals seeking medical help, resulting in a higher number of reported cases. As the global population continues to age, the prevalence of chronic diseases like asthma also increases, as the condition is not limited to any specific age group. Developing countries are witnessing a rise in asthma cases due to urbanization and industrial growth, leading to increased exposure to asthma triggers. The increasing prevalence of asthma has driven the growth of the global asthma therapeutics market. Pharmaceutical companies have been investing in research and development to create more effective treatments for asthma. The market includes a wide range of therapeutics, including inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, and monoclonal antibodies, among others.

Increasing Healthcare Expenditure

Asthma is a chronic respiratory condition that affects millions of people worldwide. With a rising prevalence of asthma and an increasing focus on healthcare, the global asthma therapeutics market is experiencing significant growth. One of the primary drivers of this growth is the increasing healthcare expenditure in various countries. As governments and healthcare organizations recognize the growing burden of chronic diseases like asthma, they are allocating larger budgets to healthcare. Increased healthcare expenditure is enabling better access to healthcare services, including improved diagnosis and management of asthma. These investments have a direct impact on the asthma therapeutics market, driving its growth. Asthma therapeutics have come a long way in recent years, thanks to advancements in medical research and technology. Pharmaceutical companies are investing heavily in the development of innovative drugs and therapies to improve asthma management. With greater healthcare spending, more resources are available for research and development, leading to the creation of more effective and efficient asthma treatments.

In many countries, the accessibility of asthma medications has improved significantly due to increased healthcare expenditure. This means that patients have better access to a wide range of asthma therapeutics, from quick-relief inhalers to long-term control medications. This improved access ensures that patients can manage their condition effectively, leading to better health outcomes. Higher healthcare spending also allows for increased asthma awareness campaigns and patient education programs. When patients are well-informed about their condition and treatment options, they are more likely to adhere to their treatment plans. This ultimately leads to better control of asthma, reducing the severity and frequency of symptoms and hospital admissions.

Research and development in the asthma therapeutics market are heavily influenced by healthcare expenditure. Greater financial support for research activities results in the discovery of new drugs and therapies that can revolutionize asthma management. These advancements benefit both patients and the pharmaceutical industry, as they create a more competitive and dynamic market. The global asthma therapeutics market is expanding as healthcare expenditure rises. In addition to the core treatment options, there is a growing interest in personalized medicine and biologics in the treatment of asthma. These innovative approaches offer a promising future for patients with severe or difficult-to-treat asthma.

While increasing healthcare expenditure is driving growth in the asthma therapeutics market, there are some challenges to address. Balancing the need for better treatments with the rising cost of healthcare is a delicate task. It's essential to ensure that healthcare resources are utilized efficiently and that affordable treatment options are available to all, regardless of socioeconomic status.

Key Market Challenges

Generic Competition

The patent expirations of several blockbuster asthma drugs have led to increased competition from generic alternatives. While this can drive down prices, it can also pose a challenge for pharmaceutical companies and innovators in terms of sustaining profitability and investing in research and development for new, innovative therapies. Asthma is a heterogeneous disease with various phenotypes and endotypes. Developing therapeutics that cater to the diverse needs of patients is a complex task. Tailoring treatments to individual asthma subtypes is challenging, as it requires a deep understanding of the underlying mechanisms and can be costly. Asthma management relies on long-term adherence to medication regimens. However, many patients struggle with non-adherence, whether due to inconvenience, side effects, or lack of understanding of the importance of consistent treatment. This can hinder the effectiveness of asthma therapeutics and result in uncontrolled asthma.

Key Market Trends

Technological Advancements

Asthma is a chronic respiratory condition that affects millions of people worldwide, causing symptoms such as wheezing, shortness of breath, and coughing. With the increasing prevalence of asthma cases globally, the demand for effective and innovative asthma therapeutics is on the rise. Technological advancements have played a pivotal role in the development of new and improved treatments, leading to a booming Global Asthma Therapeutics Market. Technological innovations have led to more accurate and efficient methods for diagnosing asthma. Traditional diagnostic methods, such as spirometry and peak flow measurements, have been supplemented with advanced diagnostic tools like exhaled nitric oxide (FeNO) testing and fractional exhaled nitric oxide (FeNO) monitors. These tools offer better insights into airway inflammation, aiding in more precise asthma diagnosis. Telemedicine has revolutionized the healthcare industry, providing convenient access to healthcare professionals and specialists. Remote monitoring devices, including smart inhalers and wearable sensors, allow patients and doctors to track asthma symptoms and medication adherence. This real-time data helps in creating personalized treatment plans and ensures better management of the condition.

Advancements in genetic research and personalized medicine have allowed for the development of targeted asthma treatments. By identifying specific genetic markers associated with asthma, pharmaceutical companies can create therapies tailored to an individual's unique genetic profile. This approach leads to more effective treatments and fewer side effects. Biologics, a class of medications derived from living organisms, have emerged as a groundbreaking treatment for severe asthma. These drugs target specific molecules in the immune system, effectively reducing inflammation and preventing asthma exacerbations. Monoclonal antibodies, a type of biologic, are increasingly used to treat severe asthma, offering hope to patients who do not respond well to traditional therapies. Inhalers have come a long way with technological advancements. Smart inhalers, equipped with Bluetooth connectivity and companion mobile apps, help patients track their inhaler usage, monitor medication adherence, and receive reminders for inhalation. These innovations enhance patient engagement and contribute to better asthma management.

AI and machine learning are invaluable tools in asthma research. They analyze vast amounts of patient data, identify patterns, and predict asthma exacerbations. Researchers use AI to develop predictive models that can guide treatment decisions and improve patient outcomes. Advanced computational modeling and virtual screening techniques are accelerating the drug discovery process. These technologies help identify potential asthma therapies faster, reducing the time and costs associated with bringing new medications to market. As a result, the pipeline for asthma drug candidates is growing rapidly.

Segmental Insights

Drug Class Insights

Based on drug class, Combination Therapy emerged as the fastest growing segment in the global market for asthma therapeutics in 2023. Combination therapy can provide better symptom control by addressing multiple aspects of asthma simultaneously. By combining a long-acting beta-agonist (LABA) with an ICS, for instance, patients can experience improved lung function, reduced inflammation, and fewer exacerbations. Asthma is not a one-size-fits-all condition. Combination therapy allows for personalized treatment regimens that can be adjusted to suit an individual's specific needs, considering factors like the severity of their asthma, their response to different medications, and comorbid conditions. Traditional reliance on SABA medications may lead to overuse and increased risk of side effects. Combination therapy can reduce the need for SABA, promoting safer, more effective asthma management. Asthma exacerbations can be severe and sometimes life-threatening. Combination therapy can significantly reduce the risk of exacerbations, leading to better long-term outcomes for asthma patients. With the development of advanced inhaler devices, patients can now conveniently administer combination therapies, making them easier to incorporate into their daily routines.

Product Insights

Based on product, the inhalers is projected to experience rapid growth in the global asthma therapeutics market during the forecast period. Inhalers deliver medication directly to the airways, ensuring that the drugs act where they are needed most. This targeted delivery reduces the risk of systemic side effects and provides faster relief. Inhalers are user-friendly and offer an easy, convenient method of medication administration. This enhances patient compliance, as individuals are more likely to adhere to their prescribed treatment plans. Inhalers typically require lower medication doses compared to oral medications. This can lead to cost savings for patients and healthcare systems and decrease the potential for adverse reactions. Inhalers come in various types, including short-acting and long-acting bronchodilators, inhaled corticosteroids, and combination therapies. This allows healthcare providers to tailor treatment regimens to the individual needs of asthma patients.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Asthma Therapeutics Market in 2023, holding the largest market share in terms of value. One of the primary reasons for North America's leading position in the global asthma therapeutics market is the high prevalence of asthma in the region. The United States, Canada, and Mexico collectively have a substantial population suffering from asthma, which drives the demand for effective asthma treatments and medications. As a result, pharmaceutical companies are heavily invested in the North American market, leading to a robust pipeline of asthma therapeutics. North America boasts a sophisticated healthcare infrastructure, characterized by state-of-the-art medical facilities, a well-trained healthcare workforce, and a strong emphasis on research and development. This conducive environment has allowed the region to excel in asthma research, enabling the development of innovative therapies and treatments. The presence of top-tier research institutions and pharmaceutical companies in North America has further contributed to the region's dominance in the asthma therapeutics market.

Key Market Players

Teva Pharmaceutical Industries Ltd.

GSK plc.

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

AstraZeneca plc.

Boehringer Ingelheim International GmbH

Sanofi S.A.

Koninklijke Philips N.V.

Becton, Dickinson and Company

Sunovion Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Asthma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Therapeutics Market, By Drug Class:

    Anti-inflammatory Combination Therapy Bronchodilators

Asthma Therapeutics Market, By Product:

    Inhalers Nebulizers

Asthma Therapeutics Market, By Route of Administration:

    Oral Inhaled Others

Asthma Therapeutics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Asthma Therapeutics Market.

Available Customizations:

Global Asthma Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Asthma Therapeutics Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators)
    • 4.2.2. By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers)
    • 4.2.3. By Route of Administration (Oral, Inhaled, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Drug Class
    • 4.3.2. By Product
    • 4.3.3. By Route of Administration
    • 4.3.4. By Region

5. Asia Pacific Asthma Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class
    • 5.2.2. By Product
    • 5.2.3. By Route of Administration
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Asthma Therapeutics Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Drug Class
        • 5.3.1.2.2. By Product
        • 5.3.1.2.3. By Route of Administration
    • 5.3.2. India Asthma Therapeutics Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Drug Class
        • 5.3.2.2.2. By Product
        • 5.3.2.2.3. By Route of Administration
    • 5.3.3. Australia Asthma Therapeutics Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Drug Class
        • 5.3.3.2.2. By Product
        • 5.3.3.2.3. By Route of Administration
    • 5.3.4. Japan Asthma Therapeutics Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Drug Class
        • 5.3.4.2.2. By Product
        • 5.3.4.2.3. By Route of Administration
    • 5.3.5. South Korea Asthma Therapeutics Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Drug Class
        • 5.3.5.2.2. By Product
        • 5.3.5.2.3. By Route of Administration

6. Europe Asthma Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Product
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Asthma Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Germany Asthma Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Spain Asthma Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Route of Administration
    • 6.3.4. Italy Asthma Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Class
        • 6.3.4.2.2. By Product
        • 6.3.4.2.3. By Route of Administration
    • 6.3.5. United Kingdom Asthma Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Class
        • 6.3.5.2.2. By Product
        • 6.3.5.2.3. By Route of Administration

7. North America Asthma Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Product
    • 7.2.3. By Route of Administration
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Asthma Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. Mexico Asthma Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. Canada Asthma Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Route of Administration

8. South America Asthma Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Product
    • 8.2.3. By Route of Administration
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Asthma Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. Argentina Asthma Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Colombia Asthma Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Route of Administration

9. Middle East and Africa Asthma Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Product
    • 9.2.3. By Route of Administration
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Asthma Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. Saudi Arabia Asthma Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. UAE Asthma Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Route of Administration

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Asthma Therapeutics Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. GSK plc.
  • 14.3. Merck & Co., Inc.
  • 14.4. F. Hoffmann-La Roche Ltd.
  • 14.5. AstraZeneca plc.
  • 14.6. Boehringer Ingelheim International GmbH
  • 14.7. Sanofi S.A.
  • 14.8. Koninklijke Philips N.V.
  • 14.9. Becton, Dickinson and Company
  • 14.10. Sunovion Pharmaceuticals, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제